注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Eyenovia Inc是一家临床阶段的眼科公司 该公司正在开发基于其微剂量阵列打印(MAP)平台技术的疗法。其产品管线专注于美国进行性近视的儿科患者和与年龄相关的近视力障碍或老花眼适应症的晚期治疗适应症的研。该公司还在开发用于散瞳的微剂量固定组合眼科药物。该公司的候选产品包括MicroLine(用于老花眼)、MicroPine(用于进行性近视)和Mydcombi(用于散瞳)。MicroLine是毛果芸香碱的微剂量版本,这是一种可以剂量依赖性地诱导瞳孔缩小或瞳孔收缩的眼科药物。MicroPine是一种用于进行性近视(一种眼后部疾病)的局部治疗药物。Mydcombi是一种用于散瞳(眼睛扩张)的固定组合微制剂候选产品。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Michael M. Rowe | 60 | 2018 | CEO & Director |
Tsontcho Ianchulev | 48 | 2014 | Co-Founder, President, Chief Medical Officer & Non-Executive Chairman |
Charles E. Mather | 62 | 2018 | Independent Director |
Ram Palanki | - | 2022 | Independent Director |
James C. Tsai | - | - | Member of Scientific Advisory Board |
Louis R. Pasquale | - | - | Member of Scientific Advisory Board |
Douglas Fredrick | - | - | Member of Scientific Advisory Board |
April Jasper | - | 2019 | Member of Scientific Advisory Board |
Shan Lin | - | - | Member of Scientific Advisory Board |
Robert N. Weinreb | - | - | Member of Scientific Advisory Board |
Rachel Jacobson | 48 | 2022 | Independent Director |
Stephen K. Benjamin | 52 | 2022 | Independent Director |
Pamela F. Gallin | - | - | Member of Scientific Advisory Board |
Mark Bullimore | - | 2019 | Member of Scientific Advisory Board |
Ellen R. Strahlman | 65 | 2022 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核